Publications
December, 2024
OKI-219
OKl-219 enhances activity of SOC therapies and drives combination responses in pre-clinical models of Pl3KαHl047R breast cancer
December, 2024
OKI-219
Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant selective inhibitor of PI3KαH1047R, in mutant selected solid tumors including breast cancer
April, 2024
OKI-219
OKI-219 is a Brain-Penetrant PI3KαH1047R Inhibitor that has increased activity in combination with SERDs
December, 2023
OKI-179
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors
December, 2023
OKI-219
Poster: OKI-219, a PI3Kα H1047R mutant-selective inhibitor demonstrates efficacy as a single agent and drives combination responses in pre-clinical PI3Kα H1047R mutant breast models
October, 2023
OKI-179
Presentation: Novel Strategy for RAS-Pathway Targeting: Initial Results from a Phase 1b/2 Clinical Trial of the Oral HDAC Inhibitor Bocodepsin (OKI-179) Combined with Binimetinib in Patients with RAS-Pathway-Mutated Solid Tumors and NRAS-Mutated Melanoma
October, 2023
OKI-179
Poster: Novel Strategy for RAS-Pathway Targeting: Initial Results from a Phase 1b/2 Clinical Trial of the Oral HDAC Inhibitor Bocodepsin (OKI-179) Combined with Binimetinib in Patients with RAS-Pathway-Mutated Solid Tumors and NRAS-Mutated Melanoma
October, 2023
OKI-219
Discovery and characterization of OKI-219, an orally bioavailable H1047R-mutant-selective inhibitor of PI3Kα
October, 2023
OKI-179
The class I Selective, Oral HDAC inhibitor Bocodepsin Enhances the Response to MAPK Pathway Inhibitors in Multiple Tumor Types with Mutations in MAPK Pathway Signaling Proteins
October, 2023
OKI-179
Utilizing a novel HDAC inhibitor bocodepsin (OKI-179) to overcome doxorubicin resistance in triple-negative breast cancer
April, 2023
CDK12
OKI-1546 is a selective, orally bioavailable inhibitor of CDK12 that causes tumor regression in multiple preclinical cancer models
April, 2022
OKI-179
The class I-targeting, oral HDAC inhibitor OKI-179 increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma
March, 2022
OKI-179
Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
August, 2021
OKI-179
Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms
October, 2020
OKI-179
Initial results from a phase 1 trial of OKI-179, an oral Class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors
October, 2020
OKI-179
Initial Results from a Phase 1 trial of OKI-179, an Oral Class 1-selective Depsipeptide HDCA Inhibitor, in Patients with Advanced Solid Tumors
January, 2020
OKI-179
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
October, 2019
OKI-179
OKI-179, A 1st in Class, Orally Administered HDAC Inhibitor with a Romidepsin-like Profile
August, 2019
OKI-179
Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas
February, 2019
OKI-179
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts